A new administration in the White House necessitates changes, but then a familiar face may be returning to the FDA. Scott Gottlieb, MD, a fellow at the American Enterprise Institute, has been nominated to run the FDA. His previous experience with the agency, as deputy commissioner for medical and scientific affairs from 2005 to 2007, is one of the many reasons the Community Oncology Alliance (COA) has strongly endorsed Gottlieb’s nomination.
Gottlieb has extensive ties to the pharmaceutical industry, which has some patient advocates worried, but Ted Okon, MBA, executive director of COA, called those concerns “nonsensical.” He called Gottlieb one of the “most knowledgeable people in this country” about the pharmaceutical industry and he believes that any ties Gottlieb may have had to the industry will not influence him in anyway once he is FDA commissioner.
Read Full Article Here >>